Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
26
DXR Quote, Financials, Valuation and Earnings
Last price:
$7.98
Seasonality move
:
14.11%
Day range:
$8.15 - $8.43
52-week range:
$7.19 - $10.04
Dividend yield:
0%
P/E ratio:
27.64x
P/S ratio:
15.35x
P/B ratio:
1.23x
Volume:
5.3K
Avg. volume:
27.9K
1-year change:
3.75%
Market cap:
$40.2M
Revenue:
$1.3M
EPS (TTM):
$0.30
Analysts' Opinion
-
Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Daxor has an estimated upside of 181.63% from its current price of $8.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $8.30.
Fair Value
-
According to the consensus of 0 analysts, Daxor has 181.63% upside to fair value with a price target of -- per share.
DXR vs. S&P 500
-
Over the past 5 trading days, Daxor has underperformed the S&P 500 by -2.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Daxor does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Daxor has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Daxor reported revenues of --.
Earnings Growth
-
Daxor has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Daxor reported earnings per share of --.
Enterprise value:
41.8M
EV / Invested capital:
--
Price / LTM sales:
15.35x
EV / EBIT:
--
EV / Revenue:
16.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
5.08%
Net Income Margin (TTM):
64.75%
Return On Equity:
5.22%
Return On Invested Capital:
5.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $335.2K | $342.6K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | $0.53 | -$0.35 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20K | $20.8K | $26.1K | $10.9K | $13.7K | |
| Total Assets | $15M | $16.7M | $22.4M | $30.4M | $34.4M | |
| Current Liabilities | $4K | -- | $16.5K | -- | -- | |
| Total Liabilities | $3.9M | $2.2M | $2.8M | -- | $1.7M | |
| Total Equity | $11.2M | $14.5M | $19.6M | $30.4M | $32.7M | |
| Total Debt | $904.7K | $1.5M | $2.8M | -- | $1.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$1.8M | -$989.9K | |
| Cash From Investing | -- | -- | -- | $6.5M | -$8.1M | |
| Cash From Financing | -- | -- | -- | -$4.7M | $9.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
DXR
Sector
Market Cap
$40.2M
$45.6M
Price % of 52-Week High
82.67%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
3.75%
-31.35%
Beta (5-Year)
-0.508
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.26
200-day SMA
Sell
Level
$9.04
Bollinger Bands (100)
Sell
Level
8.49 - 9.33
Chaikin Money Flow
Sell
Level
-6.3M
20-day SMA
Sell
Level
$8.85
Relative Strength Index (RSI14)
Sell
Level
41.57
ADX Line
Buy
Level
17.28
Williams %R
Neutral
Level
-79.8681
50-day SMA
Sell
Level
$8.94
MACD (12, 26)
Sell
Level
-0.25
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
46.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (33.31)
Buy
CA Score
(Annual)
Level (1.7392)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (8.1994)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Stock Forecast FAQ
In the current month, DXR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DXR average analyst price target in the past 3 months is --.
-
Where Will Daxor Stock Be In 1 Year?
According to analysts, the consensus estimate is that Daxor share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Daxor?
Analysts are divided on their view about Daxor share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Daxor is a Sell and believe this share price will drop from its current level to --.
-
What Is Daxor's Price Target?
The price target for Daxor over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DXR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Daxor is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DXR?
You can purchase shares of Daxor via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Daxor shares.
-
What Is The Daxor Share Price Today?
Daxor was last trading at $7.98 per share. This represents the most recent stock quote for Daxor. Yesterday, Daxor closed at $8.30 per share.
-
How To Buy Daxor Stock Online?
In order to purchase Daxor stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.33% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.77% over the past day.
